Exelixis discovers and develops next‑generation oncology therapeutics using both in‑house small‑molecule platforms and biotherapeutic modalities such as bispecific antibodies and antibody‑drug conjugates. By targeting diverse molecular mechanisms and partnering with pharmaceutical companies, it advances a pipeline of novel cancer medicines from preclinical research through clinical trials to expand treatment options for advanced and resistant tumors.
Funding
$135M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with cancer often have limited treatment options, especially for advanced or metastatic disease, due to a lack of therapies that target diverse molecular mechanisms. This gap leads to suboptimal outcomes and a continued need for innovative medicines that can address resistance and improve survival.
Solution
Exelixis focuses on discovering and developing next‑generation oncology therapeutics across multiple platforms. The company leverages deep chemistry and biology expertise to create both small‑molecule drugs and biotherapeutics such as bispecific antibodies and antibody‑drug conjugates. By pursuing novel mechanisms of action and first‑in‑class targets, Exelixis aims to expand treatment options for a broad range of tumor types. Strategic collaborations with other industry partners accelerate the translation of research into clinical candidates, while an integrated pipeline moves promising agents through preclinical and clinical stages toward regulatory approval.
Target Audience
Primary customers are pharmaceutical partners, oncology researchers, and clinicians seeking novel therapeutic options for patients with advanced or treatment‑resistant cancers.
Features
- In‑house small‑molecule discovery platform targeting diverse oncogenic pathways
- Development of biotherapeutics, including bispecific antibodies and antibody‑drug conjugates
- Application of multiple modalities and mechanisms of action to address resistance
- Collaborative partnership model that combines external expertise with internal capabilities
- Robust clinical‑trial program advancing candidates from early‑stage to late‑stage studies
- Focus on combination regimens with immune checkpoint inhibitors for enhanced efficacy